Vera Therapeutics, Inc. (VERA) Income Statement

The absence of revenue means the growth narrative is entirely cost-driven, not top-line driven. Operating losses have more than tripled over the observed ten quarters, with the steepest sequential jump occurring between 2025Q1 and 2025Q2 as R&D spending rose from $41.3M to $58.1M. This trajectory suggests the company is deliberately front-loading clinical trial expenses ahead of potential regulatory milestones, but investors should monitor whether the pace of cash consumption aligns with trial enrollment and data readout timelines.

The cost structure is bifurcating: R&D remains the largest line item, but SG&A is growing at a faster clip, nearly doubling between 2025Q4 and 2026Q2. This suggests management is not only funding the Phase 3 ORIGIN trial but also preparing for potential commercialization, which may indicate confidence in the pipeline. However, the rapid SG&A escalation without revenue creates a higher fixed-cost base that will pressure margins even after approval, unless the drug achieves rapid uptake.

With no revenue, operating leverage is structurally negative; every incremental dollar of R&D or SG&A directly widens the operating loss. The sequential increase in operating losses from $94.2M in 2025Q4 to $112.5M in 2026Q2 was driven by a $17.5M jump in SG&A, not R&D, which actually declined from $86.0M to $60.1M. This suggests management may be shifting focus toward launch readiness, but the lack of revenue means the company cannot benefit from scale economies until atacicept is approved and commercialized.

This inflection is the single most important operational shift in the income statement history, as it moved the company from proof-of-concept to regulatory execution. The sustained elevation in R&D spending through 2026Q2, despite quarterly fluctuations, indicates the trial is in full enrollment and data collection mode. The lasting impact is a permanently higher cost base that will persist until either approval generates revenue or the program is terminated, making the next 12-18 months critical for cash management.